Miami-headquartered Summit Therapeutics Inc. expanded rights to Akeso Inc.’s non-small-cell lung cancer (NSCLC) drug, ivonescimab (SMT-112; AK-112), June 3 while raising $200 million to advance the therapy.

Despite the ongoing war, speakers at Biomed Israel this week reported that business and investment in Israel’s med-tech industry continues largely unchanged.

Early-stage health care companies developing breakthrough medical technologies were given some good news recently with the launch of a new accelerator program by Israel’s Arc Innovation aimed at giving startups a $250,000 cash injection. With a $10 million investment from Ilex Medical Ltd., the initiative is looking to empower early-stage companies by providing financial backing, expert guidance and a support network.